Barrington Research Comments on Surmodics FY2025 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Barrington Research raised their FY2025 earnings per share estimates for shares of Surmodics in a note issued to investors on Thursday, November 7th. Barrington Research analyst M. Petusky now forecasts that the company will earn $0.21 per share for the year, up from their previous estimate of $0.19. The consensus estimate for Surmodics’ current full-year earnings is $0.16 per share. Barrington Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.17 EPS.

Several other equities analysts also recently commented on the stock. StockNews.com began coverage on shares of Surmodics in a report on Thursday. They set a “hold” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research note on Thursday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Surmodics presently has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Trading Down 0.2 %

SRDX stock opened at $38.40 on Friday. The firm’s fifty day simple moving average is $38.60 and its two-hundred day simple moving average is $38.60. The company has a current ratio of 3.98, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. Surmodics has a twelve month low of $25.17 and a twelve month high of $42.44.

Institutional Investors Weigh In On Surmodics

Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of Surmodics by 7.5% during the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after acquiring an additional 481 shares in the last quarter. SG Americas Securities LLC raised its position in Surmodics by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after purchasing an additional 660 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Surmodics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 865,214 shares of the company’s stock worth $25,385,000 after buying an additional 5,927 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Surmodics by 11.3% in the 1st quarter. Acadian Asset Management LLC now owns 408,779 shares of the company’s stock worth $11,988,000 after buying an additional 41,617 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Surmodics during the 1st quarter worth $1,270,000. 96.63% of the stock is owned by hedge funds and other institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).